



2014-03-31

PRESS RELEASE

Publication of change in the total number of shares and votes in Oasmia

The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 85 572 330 as of March 31, 2014. The increase in the number of shares is attributable to a private placement carried out in March 2014, which comprised 3 800 000 shares. The share issue was registered in its entirety with the Swedish Companies Registration Office on March 14, 2014.

A list of the company principal shareholders will be available at www.oasmia.com

For more information, please contact:

Mikael Widell, Vice President Communications

Mobile: +46 70 311 99 60

E-mail: mikael.widell@oasmia.com

Notes to editors:

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).

Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 09.00, CET on March 31, 2014."